Last reviewed · How we verify

NCT05483725

Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.

Status unknown Last updated 6 March 2024
What this trial tests

trial testing Booster dose of mRNA vaccine in Kidney Diseases in 108 participants. Status unknown.

Timeline
4 October 2021
Primary endpoint
4 December 2024
31 December 2024

Quick facts

Lead sponsorInstitute for Clinical and Experimental Medicine
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment108
Start date4 October 2021
Primary completion4 December 2024
Estimated completion31 December 2024
Sites1 location across Czechia

Drugs / interventions tested

Conditions studied

Sponsor

Institute for Clinical and Experimental Medicine

Who can join

18 and older, any sex, with Kidney Diseases or Kidney Transplant; Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective observational trial to assess immunological safety (anti-HLA antibodies, donor-derived cell-free DNA) and immunological effectiveness (anti-SARS-CoV-2 IgG) of the first booster dose of SARS-CoV-2 mRNA vaccines in kidney transplant recipients at least one year from transplantation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine Booster Doses in Kidney Transplant Recipients: Results of a 12-mo Follow-up From a Prospective Observational Study.
    Petr V, Zahradka I, Modos I, Roder M, et al · · 2024 · cited 1× · PMID 38769974 · DOI 10.1097/txd.0000000000001645

Verify or expand the search:

Other recruiting trials for Kidney Diseases

Currently open trials in the same condition.

Other Institute for Clinical and Experimental Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05483725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing